Faculty Opinions recommendation of Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

2013 ◽  
Author(s):  
Cihan Yurdaydin
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Users ◽  
Meta Analysis ◽  
Treatment Completion

scholarly journals Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis

2012 ◽  
Vol 56 (6) ◽  
pp. 806-816 ◽  
Author(s):  
Rositsa B. Dimova ◽  
Marija Zeremski ◽  
Ira M. Jacobson ◽  
Holly Hagan ◽  
Don C. Des Jarlais ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Users ◽  
Meta Analysis ◽  
Treatment Completion

scholarly journals High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001–2012)

2015 ◽  
Vol 40 ◽  
pp. 116-130 ◽  
Author(s):  
Mohsen Malekinejad ◽  
Soodabeh Navadeh ◽  
Ali Lotfizadeh ◽  
Afarin Rahimi-Movaghar ◽  
Masoumeh Amin-Esmaeili ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Users ◽  
Meta Analysis ◽  
Epidemiological Evidence ◽  
Virus Prevalence

scholarly journals Factors Correlating to the Development of Hepatitis C Virus Infection among Drug Users—Findings from a Systematic Review and Meta-Analysis

2019 ◽  
Vol 16 (13) ◽  
pp. 2345 ◽  
Author(s):  
Biao Zhou ◽  
Gao Feng Cai ◽  
Hua Kun Lv ◽  
Shuang Fei Xu ◽  
Zheng Ting Wang ◽  
...  
Keyword(s):  
Sexual Behavior ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Use ◽  
Drug Users ◽  
Methadone Maintenance ◽  
Meta Analysis ◽  
Injecting Drug Use ◽  
Hcv Infection ◽  
Increased Risk

Hepatitis C remains a significant public health threat. However, the main routes of transmission have changed since the early 1990s. Currently, drug use is the main source of hepatitis C virus (HCV) infection, and some measures have been successively implemented and additional studies have been published. However, the factors correlating with HCV infection failed to clearly define. Our study pooled the odds ratios (ORs) with 95% confidence intervals (CIs) and analyzed sensitivity by searching data in the PubMed, Elsevier, Springer, Wiley, and EBSCO databases. Publication bias was determined by Egger’s test. In our meta-analysis, HCV-infected and non-HCV-infected patients from 49 studies were analyzed. The pooled ORs with 95% CIs for study factors were as follows: Injecting drug use 10.11 (8.54, 11.97); sharing needles and syringes 2.24 (1.78, 2.83); duration of drug use >5 years 2.39 (1.54, 3.71); unemployment 1.50 (1.22, 1.85); commercial sexual behavior 1.00 (0.73, 1.38); married or cohabiting with a regular partner 0.88 (0.79, 0.98), and sexual behavior without a condom 1.72 (1.07, 2.78). This study found that drug users with histories of injecting drug use, sharing needles and syringes, drug use duration of >5 years, and unemployment, were at increased risk of HCV infection. Our findings indicate that sterile needles and syringes should be made available to ensure safe injection. In view of that, methadone maintenance treatment can reduce or put an end to risky drug-use behaviors, and should be scaled up further, thereby reducing HCV infection.

Prevalence and Distribution of Hepatitis C Virus in Iranian Drug User: Systematic Review and Meta-Analysis Study

2020 ◽  
Author(s):  
Alireza Najimi-Varzaneh ◽  
Mohammad Gholami-Fesharaki
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug User ◽  
Drug Users ◽  
Meta Analysis ◽  
Scientific Information ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Analysis Study ◽  
Hcv Prevalence

Context: Hepatitis C, as a major public health problem, has serious complications and drug users are the highest risk group for it.Objectives: As the importance of this subject, the current study has been done to estimate the pooled prevalence  and distribution of hepatitis c virus in Iranian Drug User.Evidence Acquisition: Articles were identified through international searching databases including PubMed, Scopus, Elsevier, Google Scholar and Web of Science and Iranian scientific information database (SID), Health. barakatkns, IranDoc, Civilica and MagIran. We reviewed systematically all studies reporting the prevalence of HCV Iranian Drug User.Results: 227 records were identified by the electronic search, of which 62 studies were identified as relevant  papers which were meta-analyzed for the pooled HCV prevalence. Overall, prevalence of HCV  was 42.01 %( 36.83%-47.20%) in Iranian drug user.Conclusion: Our meta-analysis study showed that HCV prevalence is high in drug users in Iran. With respect to the high prevalence of Hepatitis C among Drug User, ongoing preventive actions for this group are recommended.

scholarly journals Hepatitis C virus and HIV type 1 co-infection

2013 ◽  
Vol 5 (1S) ◽  
pp. 7 ◽  
Author(s):  
Priyanka Gupta
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hiv Infection ◽  
Drug Users ◽  
Liver Toxicity ◽  
Meta Analysis ◽  
Hcv Infection ◽  
Increased Risk ◽  
Risk Of Progression

Around 33 million people worldwide are living with Human Immunodeficiency Virus (HIV) infection, and approximately 20-30% of HIV-infected individuals are also infected with Hepatitis C virus (HCV). The main form of HCV transmission is via the blood borne route; high rates of co-infection are found in intravenous drug users with HCV prevalence rates as high as 90%. Introduction of effective anti-retroviral therapy (ART) has led to a significant decline in HIV-related morbidity, but at the same time the incidence of HCV related liver disease is increasing in the co-infected population. Meta analysis has revealed that individuals who are co-infected with HIV/HCV harbor three times greater risk of progression to liver disease than those infected with HCV alone. Increased risk of progression to Acquired Immunodeficiency Syndrome (AIDS) and AIDS-related deaths is shown among the co-infected patients by some studies, suggesting that HCV infection may accelerate the clinical course of HIV infection. HCV may also affect the incidence of liver toxicity associated with ART, affecting the management of HIV infection. There is a lack of optimal therapeutic approaches to treat HCV infection in HIV co-infected patients. This review discusses recent literature pertaining HIV/HCV co-infection, in addition to providing a snapshot of impact of co-infection on human genome at the level of gene expression and its regulation by microRNAs (miRNAs).

New Epidemiologic Data Regarding Hepatitis C Virus Infection in Romania

2017 ◽  
Vol 26 (4) ◽  
pp. 381-386
Author(s):  
Mircea Manuc ◽  
Carmen M. Preda ◽  
Corneliu P. Popescu ◽  
Cristian Baicuș ◽  
Theodor Voiosu ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Drug Users ◽  
Antiviral Agent ◽  
Virologic Response ◽  
Advanced Fibrosis ◽  
Direct Acting Antiviral ◽  
Genotype 1B ◽  
Direct Acting ◽  
End Stage

Background & Aims: Literature data suggest that HCV genotype-1b is present in 93-99% of the Romanian patients infected with hepatitis C virus (HCV). We present the genotyping tests recently performed on patients with HCV and advanced fibrosis eligible for the Direct-Acting Antiviral (DAA) therapy, as well as the prevalence of these cases across Romania.Methods: The genotyping method was performed on 7,421 HCV patients with advanced fibrosis. The detection method was automatic real time PCR platform M2000 (Abbott). Every subject was introduced into a database including age, sex, county and address.Results: Genotype 1b was almost exclusively present: 7,392/7,421 (99.6%). Genotype 1b patients were 19.6% from Bucharest, 49% were males, with a median age of 60 years. Genotype non-1b was encountered in 29/7,421 subjects (0.4%), 62% were males, 69% from Bucharest and the median age was 52 years. Most of the subjects (75%) were in the 6th and 7th age decade. The prevalence of these cases varied significantly across Romanian counties: the highest was in Bucharest (61.3/105), Bihor (47/105), Iasi (46/105) and Constanța (43/105), and the lowest in Ilfov (2.8/105), Harghita (3.7/105), Covasna (5.4/105) and Maramureș (8.8/105) (p<0.001).Conclusions: Genotype 1b is encountered in 99.6% of patients with chronic hepatitis C and advanced fibrosis from Romania. The presence of genotypes non-1b is more common in Bucharest, in males and at a younger age. There are significant differences regarding the distribution of these cases across Romania: the highest rates are in Bucharest, Bihor, Iasi and Constanta.Abbreviations: BMI: body mass index; DAA: direct-acting antiviral agent; GT: genotype; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; IDU: intravenous drug users; MELD: model for end stage liver disease; NASH: non-alcoholic steatohepatitis; SVR; sustained virologic response.

Sign in / Sign up

Export Citation Format

Share Document